Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Preston

Showing results (41-50 of 135) with videos related to

Pageof 14
Sort By:
Urologic Oncology|July 13, 2024
Risk of cardiovascular events following intermittent and continuous androgen deprivation therapy in patients with nonmetastatic prostate cancerMark A Preston, Ramin Ebrahimi, Agnes Hong, et al.
European Urology|December 17, 2018
Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment OutcomesMohammad Abufaraj, Beat Foerster, Eva Schernhammer, et al.
World Journal of Surgery|June 11, 2015
The Effect of Body Mass Index on Perioperative Outcomes After Major Surgery: Results from the National Surgical Quality Improvement Program (ACS-NSQIP) 2005-2011Akshay Sood, Firas Abdollah, Jesse D Sammon, et al.
European Urology|January 4, 2011
The prognostic significance of capsular incision into tumor during radical prostatectomyMark A Preston, Mathieu Carrière, Gaayana Raju, et al.
Clinical Genitourinary Cancer|March 7, 2019
Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive TherapyPhilipp Gild, David-Dan Nguyen, Sean A Fletcher, et al.
JAMA Oncology|January 1, 2016
Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation TherapyMaxine Sun, Toni K Choueiri, Ole-Petter R Hamnvik, et al.
Journal of Clinical Medicine|November 14, 2023
Evidence-Based Analysis of the Critical Steps of Radical Cystectomy for Bladder CancerVincent D D'Andrea, Kevin Melnick, Kendrick Yim, et al.
Future Oncology (London, England)|April 1, 2025
Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patientsRana R McKay, Ashley E Ross, Mark A Preston, et al.
World Journal of Urology|November 18, 2018
Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categoriesMatthew Mossanen, Ye Wang, Julie Szymaniak, et al.
Urology|April 9, 2020
Alvimopan Is Associated With a Reduction in Length of Stay and Hospital Costs for Patients Undergoing Radical CystectomyJay Tzu-Hao Huang, Alexander P Cole, Matthew Mossanen, et al.
Pageof 14

Showing results (41-50 of 135) with videos related to

Sort By:
Pageof 14
Urologic Oncology|July 13, 2024
Risk of cardiovascular events following intermittent and continuous androgen deprivation therapy in patients with nonmetastatic prostate cancerMark A Preston, Ramin Ebrahimi, Agnes Hong, et al.
European Urology|December 17, 2018
Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment OutcomesMohammad Abufaraj, Beat Foerster, Eva Schernhammer, et al.
World Journal of Surgery|June 11, 2015
The Effect of Body Mass Index on Perioperative Outcomes After Major Surgery: Results from the National Surgical Quality Improvement Program (ACS-NSQIP) 2005-2011Akshay Sood, Firas Abdollah, Jesse D Sammon, et al.
European Urology|January 4, 2011
The prognostic significance of capsular incision into tumor during radical prostatectomyMark A Preston, Mathieu Carrière, Gaayana Raju, et al.
Clinical Genitourinary Cancer|March 7, 2019
Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive TherapyPhilipp Gild, David-Dan Nguyen, Sean A Fletcher, et al.
JAMA Oncology|January 1, 2016
Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation TherapyMaxine Sun, Toni K Choueiri, Ole-Petter R Hamnvik, et al.
Journal of Clinical Medicine|November 14, 2023
Evidence-Based Analysis of the Critical Steps of Radical Cystectomy for Bladder CancerVincent D D'Andrea, Kevin Melnick, Kendrick Yim, et al.
Future Oncology (London, England)|April 1, 2025
Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patientsRana R McKay, Ashley E Ross, Mark A Preston, et al.
World Journal of Urology|November 18, 2018
Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categoriesMatthew Mossanen, Ye Wang, Julie Szymaniak, et al.
Urology|April 9, 2020
Alvimopan Is Associated With a Reduction in Length of Stay and Hospital Costs for Patients Undergoing Radical CystectomyJay Tzu-Hao Huang, Alexander P Cole, Matthew Mossanen, et al.
Pageof 14